Merck to acquire biotech company Prometheus Biosciences for $10.8bn
Merck has agreed to acquire Prometheus Biosciences, a Nasdaq-listed clinical-stage biotechnology company, in an all-cash deal worth around $10.8 billion, in a move to bolster its immunology pipeline. The California-based Prometheus Biosciences is engaged in the discovery, development, and commercialization of therapeutic and companion diagnostic products for the treatment of immune-mediated diseases by using a […]
